METHOD AND APPARATUS FOR SURFACE PLASMON RESONANCE IMAGING

    公开(公告)号:US20220011228A1

    公开(公告)日:2022-01-13

    申请号:US17282163

    申请日:2019-10-03

    Abstract: A method and apparatus for surface plasmon resonance imaging are provided for imaging the surface plasmon resonance signals caused by the interaction of biomolecules. In particular, the method and apparatus can image the slightly spectral change in a surface plasmon resonance mode by comparing the light intensities of two bands in the frequency domain of the surface plasmon.

    ANTI-CD20 GLYCOANTIBODIES AND USES THEREOF

    公开(公告)号:US20210332146A1

    公开(公告)日:2021-10-28

    申请号:US17211619

    申请日:2021-03-24

    Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

    INHIBITION OF SCUBE2, A NOVEL VEGFR2 CO-RECEPTOR, SUPPRESSES TUMOR ANGIOGENESIS

    公开(公告)号:US20210292401A1

    公开(公告)日:2021-09-23

    申请号:US17342514

    申请日:2021-06-08

    Abstract: An isolated anti-SCUBE2 antibody or a binding fragment thereof is disclosed. The anti-SCUBE2 antibody comprises an antigen binding region that specifically binds to a target domain located within SCUBE2 (SEQ ID NO: 66) and exhibits a property of inhibiting VEGF-induced angiogenesis. The target domain is selected from the group consisting of the EGF-like motifs 4 to 6 ranging from a.a. position 175 to 323, or the spacer region ranging from a.a. position 441 to 659, or the first cys-rich motif ranging from a.a. position 668 to 725 of SCUBE2 (SEQ ID NO: 66). The anti-SCUBE2 antibody or binding fragment thereof is for use in treating a disease associated with VEGF-induced angiogenesis, or for use in treating a tumor or inhibiting tumor angiogenesis and cancer cell growth in a subject in need thereof.

Patent Agency Ranking